Episodic Src activation in uveal melanoma revealed by kinase activity profiling

British Journal of Cancer

Volumn 101, Issue 2, 2009, Pages 312-319

  Maat, W ^a   Filali, M El ^a   Dirks Mulder, A ^b   Luyten, G P M ^a   Gruis, N A ^a   Desjardins, L ^c   Boender, P ^d   Jager, M J ^a   Van Der Velden, P A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF APPLIED SCIENCES LEIDEN   (Netherlands)

^c INSTITUT CURIE   (France)

^d PamGene   (Netherlands)

Author keywords

ERK; Src; Tyrosine kinase; Uveal melanoma

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; PROTEIN TYROSINE KINASE;

AMINO ACID SEQUENCE; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; MELANOCYTE; METASTASIS; PRIORITY JOURNAL; UVEA MELANOMA; CELL GROWTH; ENZYMOLOGY; HUMAN; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UVEA TUMOR;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM METASTASIS; SRC-FAMILY KINASES; UVEAL NEOPLASMS;

EID: 67650641873     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605172     Document Type: Article

References (41)

1. Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F (2008) HSP90 inhibitors 17-AAG and 17-DMAG target wild-type B-Raf signaling for the proliferation of human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 49: 2348-2356
2. Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, Mascarelli F (2006) Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. J Biol Chem 281: 9238-9250
3. Chen PW, Murray TG, Salgaller ML, Ksander BR (1997) Expression of MAGE genes in ocular melanoma cell lines. J Immunother 20: 265-275
4. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J, Sidransky D (2003) Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44: 2876-2878
5. Cooper JA, Reiss NA, Schwartz RJ, Hunter T (1983) Three glycolytic enzymes are phosphorylated at tyrosine in cells transformed by Rous sarcoma virus. Nature 302: 218-223
6. Cruz III F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63: 5761-5766
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
8. Diella F, Cameron S, Gemund C, Linding R, Via A, Kuster B, Sicheritz-Ponten T, Blom N, Gibson TJ (2004) Phospho.ELM: a database of experimentally verified phosphorylation sites in eukaryotic proteins. BMC Bioinformatics 5: 79
9. Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88: 1403-1405
10. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM (1988) Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32: 239-251
11. Faingold D, Marshall JC, Antecka E, Di Cesare S, Odashiro AN, Bakalian S, Fernandes BF, Burnier Jr MN (2008) Immune expression and inhibition of heat shock protein 90 in uveal melanoma. Clin Cancer Res 14: 847-855
12. Goding CR (2000) Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 14: 1712-1728
13. Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC (2009) Over-expression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 15: 324-329
14. Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, Roberts F (2008) The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer 99: 1673-1677
15. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE (1989) Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 30: 829-834
16. Koike A, Kobayashi Y, Takagi T (2003) Kinase pathway database: an integrated protein-kinase and NLP-based protein-interaction resource. Genome Res 13: 1231-1243
17. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, Maurage CA, Auclair C, Mascarelli F (2004) Roles of stem cell factor/ c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 279: 31769-31779
18. Lemeer S, Jopling C, Naji F, Ruijtenbeek R, Slijper M, Heck AJ, den Hertog J (2007) Protein-tyrosine kinase activity profiling in knock down zebrafish embryos. PLoS ONE 2: e581
19. Luyten GP, Naus NC, Mooy CM, Hagemeijer A, Kan-Mitchell J, Van Drunen E, Vuzevski V, de Jong PT, Luider TM (1996) Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer 66: 380-387
20. Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, van der Velden PA (2008) Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 49: 23-27
21. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V, Loning T (2005) Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92: 2206-2215
22. Missotten GS, Journee-de Korver JG, Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ (2003) Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci 44: 3059-3065
23. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M (2007) Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 98: 652-658
24. Mooy CM, Van der Helm MJ, Van der Kwast TH, de Jong PT, Ruiter DJ, Zwarthoff EC (1991) No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. Br J Cancer 64: 411-413
25. Narayanan R, Kenney MC, Kamjoo S, Trinh TH, Seigel GM, Resende GP, Kuppermann BD (2005) Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells. Invest Ophthalmol Vis Sci 46: 304-309
26. Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403
27. Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63: 5712-5715
28. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759
29. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602
30. Singh AD, Topham A (2003) Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 110: 956-961
31. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, (Article 3)
32. Soparker CN, O'Brien JM, Albert DM (1993) Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci 34: 2203-2209
33. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001-5014
34. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358
35. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609
36. van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ (2001) Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res 61: 5303-5306
37. van Elsas A, Zerp S, van der FS, Kruse-Wolters M, Vacca A, Ruiter DJ, Schrier P (1995) Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/ single-stranded conformation polymorphism analysis. Recent Results Cancer Res 139: 57-67
38. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC (2008) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229): 599-602
39. Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, Danen EH, Jager MJ (1995) Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 62: 155-161
40. Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A (2003) Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 83: 1771-1776
41. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, Pavey S, van der Velden PA, Out C, Jager MJ, Hayward NK, Gruis NA (2005) Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 92: 2032-2038